EVIDENCE-BASED VALUE OF PD-1 / PD-L1 INHIBITORS IN NSCLC: COMPARISON OF VALUE TO PRICE

被引：0
|
作者：
Doyle, J. J. [1 ]
Wood, B. [1 ]
机构：
[1] IQVIA, New York, NY USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.536
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCP61
引用
收藏
页码：S91 / S91
页数：1
相关论文
共 50 条
  • [31] Trends in clinical development for PD-1/PD-L1 inhibitors
    Yu, Jia Xin
    Hodge, Jeffrey P.
    Oliva, Cristina
    Neftelinov, Svetoslav T.
    Hubbard-Lucey, Vanessa M.
    Tang, Jun
    NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (03) : 163 - 164
  • [32] Whole Body PD-1 and PD-L1 PET in Pts with NSCLC
    Niemeijer, A.
    Smit, E.
    Van Dongen, G.
    Windhorst, A. D.
    Huisman, M.
    Hendrikse, N.
    Bahce, I.
    Lueng, D.
    Smith, R.
    Hayes, W.
    Wilson, L.
    Bonacorsi, S.
    Donnelly, D.
    Morin, P.
    Poot, A.
    Vugts, D.
    Thunnissen, E.
    De Langen, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1817 - S1817
  • [33] Expression Patterns and Prognostic Value of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma
    Owen, Dwight
    Chu, Benjamin
    Lehman, Amy
    Annamalai, Lakshmanan
    Yearley, Jennifer
    Shilo, Konstantin
    Otterson, Gregory
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1008 - S1009
  • [34] Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
    Jelinek, Tomas
    Paiva, Bruno
    Hajek, Roman
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [35] Progress on biphenyl derivatives as PD-1/PD-L1 inhibitors
    Shurong Wang
    Yuli Wang
    Hong Yan
    Medicinal Chemistry Research, 2023, 32 : 2089 - 2115
  • [36] Combinations of Chemotherapy and PD-1/PD-L1 Inhibitors in Sarcoma
    Lynch, Meghan M.
    Alexiev, Borislav A.
    Schroeder, Brett A.
    Pollack, Seth M.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (12) : 1861 - 1876
  • [37] Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model
    Wu, Yingcheng
    Lin, Lifeng
    Shen, Yanting
    Wu, Huiqun
    INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (11) : 3038 - 3040
  • [38] The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis
    Yang, Yao
    Chen, Dongbo
    Zhao, Bigeng
    Ren, Liying
    Huang, Rui
    Feng, Bo
    Chen, Hongsong
    CANCER MEDICINE, 2023, 12 (08): : 9282 - 9292
  • [39] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
    Duruisseaux, Michael
    Rouquette, Isabelle
    Adam, Julien
    Cortot, Alexis
    Cazes, Aurelie
    Gibault, Laure
    Damotte, Diane
    Lantuejoul, Sylvie
    ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
  • [40] Beyond inhibition against the PD-1/PD-L1 pathway: development of PD-L1 inhibitors targeting internalization and degradation of PD-L1
    Guo, Jiazheng
    Yu, Fengyi
    Zhang, Kuojun
    Jiang, Sheng
    Zhang, Xiangyu
    Wang, Tianyu
    RSC MEDICINAL CHEMISTRY, 2024, 15 (04): : 1096 - 1108
12345